Business Description
Applied Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US03828A1016
Description
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 427.07 | |||||
| Equity-to-Asset | 0.45 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -5.02 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 43.8 | |||||
| 3-Year EPS without NRI Growth Rate | 44.1 | |||||
| 3-Year FCF Growth Rate | 43.1 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 35.2 | |||||
| 9-Day RSI | 38.01 | |||||
| 14-Day RSI | 39.87 | |||||
| 6-1 Month Momentum % | 142.66 | |||||
| 12-1 Month Momentum % | 229.84 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.8 | |||||
| Quick Ratio | 1.8 | |||||
| Cash Ratio | 1.75 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -55.7 | |||||
| Shareholder Yield % | -32.08 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | 15675.47 | |||||
| Net Margin % | 40579.46 | |||||
| FCF Margin % | 14181.92 | |||||
| ROE % | -3152.71 | |||||
| ROA % | -297.87 | |||||
| ROIC % | -176.35 | |||||
| ROC (Joel Greenblatt) % | -11510.47 | |||||
| ROCE % | -1103.42 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 7.88 | |||||
| Price-to-Tangible-Book | 7.52 | |||||
| EV-to-EBIT | -4.76 | |||||
| EV-to-Forward-EBIT | -5.28 | |||||
| EV-to-EBITDA | -4.78 | |||||
| EV-to-Forward-EBITDA | -5.28 | |||||
| EV-to-Revenue | -746.21 | |||||
| EV-to-Forward-Revenue | 115.7 | |||||
| EV-to-FCF | -5.72 | |||||
| Price-to-Net-Current-Asset-Value | 7.52 | |||||
| Price-to-Net-Cash | 8.12 | |||||
| Earnings Yield (Greenblatt) % | -21 | |||||
| FCF Yield % | -13.37 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Applied Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | -0.437 | ||
| EPS (TTM) (€) | -1.701 | ||
| Beta | 2.09 | ||
| Volatility % | 184.65 | ||
| 14-Day RSI | 39.87 | ||
| 14-Day ATR (€) | 0.1771 | ||
| 20-Day SMA (€) | 4.1975 | ||
| 12-1 Month Momentum % | 229.84 | ||
| 52-Week Range (€) | 1.148 - 6.85 | ||
| Shares Outstanding (Mil) | 114.27 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Applied Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Applied Therapeutics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Applied Therapeutics Inc Frequently Asked Questions
What is Applied Therapeutics Inc(STU:2UV)'s stock price today?
The current price of STU:2UV is €4.06. The 52 week high of STU:2UV is €6.85 and 52 week low is €1.15.
When is next earnings date of Applied Therapeutics Inc(STU:2UV)?
The next earnings date of Applied Therapeutics Inc(STU:2UV) is .
Does Applied Therapeutics Inc(STU:2UV) pay dividends? If so, how much?
Applied Therapeutics Inc(STU:2UV) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers